THERAPY DOSSIER · th-33ad0d0a9990

Methanolic extract of Ephedra ciliata (quercetin-rich)

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32385747 ↗2020Reported benefit

Methanolic extract of Ephedra ciliata promotes wound healing and arrests inflammatory cascade in vivo through downregulation of TNF-alpha.

RatWoundMale and femaleTopical (wound models); systemic (anti-inflammatory models)20% cream topically for wound models; 200 mg/kg for anti-in…After wounding

Model: Excision and burn skin wounds, with carrageenan paw oedema and cotton pellet granuloma inflammation models

The quercetin-rich extract promoted dose and time-dependent wound closure comparable with heparin, inhibited granuloma formation, improved skin histological architecture, downregulated serum TNF-alpha and showed no adverse effect on vascular development.

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…